21/11/22 -"The increase in our EPS estimate is attributable to the upgraded FY22 guidance, which includes: 1) same-day sales growth of c.12% (vs 7-9% previously), and 2) an adjusted EBITA margin of c. 7.2% (vs ..."
Pages
47
Language
English
Published on
21/11/22
You may also be interested by these reports :
29/03/23
The outlook for the German online pharmacy market in 2023E is positive. Zur Rose G. lost market share in 2022
29/03/23
The divestment of group’s Swiss business will delay the way to adj. EBITDA profitability; Add confirmed but lower TP
23/03/23
We now take a more conservative view on Currys’ performance in the Nordics segment (c.40% of group revenue and c.47% operating profit in FY21/22). ...
23/03/23
FY23E: Sales to decline yoy, adj. EBITDA break-even postponed to FY24E